# A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

> **NCT05107128** · PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 189 (actual)

## Conditions studied

- Huntington's Disease

## Interventions

- **DRUG:** SAGE-718
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05107128
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-26
- **Primary completion:** 2024-09-04
- **Final completion:** 2024-10-03
- **Target enrollment:** 189 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107128

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107128, "A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05107128. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*